The relevance of evolving grey and white matter pathology to the development of neurodegeneration and disability in multiple sclerosis
- Conditions
- Multiple SclerosisNervous System Diseases
- Registration Number
- ISRCTN61223124
- Lead Sponsor
- niversity College London
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 140
1. Included in the original research study (ref: 917/09).
2. Aged 18-65 years (at time of original study)
3. Able to undertake written informed consent in English
4. Diagnosis of clinically definite MS or were healthy controls with no known neurological disease
1. Involvement in other research studies or medical interventions which might have contraindications for this study
2. Neurological disease other than CIS and MS that impedes study interpretation
3. Contraindication to MRI scanning is not an exclusion criteria for the study, however participants must meet safety criteria to take part in this element of the study. Participants will be asked to complete the NMR Research Unit’s MRI safety checklist to determine whether or not it is safe to proceed with MRI scanning.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Cortical grey matter atrophy measured using 3D T1-weighted volumetric MRI scans at the single study visit<br> 2. Transition to secondary progressive MS measured using clinical assessment based on history and examination at the single study visit<br> 3. Disability accrual measured using the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and cognitive measures at the single study visit<br>
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures